MB
RCKT icon

MPM BioImpact’s Rocket Pharmaceuticals RCKT Stock Holding History

MPM BioImpact’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,586,076
Closed -$5.57M – 46
2025
Q4 		$5.57M Sell
1,586,076
-2,317,305
-59% -$7.93M 0.64% 34
2025
Q3 		$12.7M Buy
3,903,381
+300
+0% +$945 2.08% 23
2025
Q2 		$9.56M Buy
3,903,081
+2,284,816
+141% +$11.6M 1.66% 29
2025
Q1 		$10.8M Buy
1,618,265
+597,706
+59% +$5.91M 1.86% 22
2024
Q4 		$12.8M Sell
1,020,559
-45,814
-4% -$690K 1.82% 23
2024
Q3 		$19.7M Buy
+1,066,373
New +$21.8M 2.95% 9

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MPM BioImpact's RCKT Position: Q1 2026 in Review

MPM BioImpact sold out of Rocket Pharmaceuticals (RCKT) in Q1 2026, closing a stake of 1,586,076 shares — an estimated $5.57M sold.

MPM BioImpact first reported a position in RCKT in Q3 2024 and held it in 6 quarters. The position peaked at $19.7M in Q3 2024. 199 funds tracked by Wall St. Rank hold RCKT as of Q1 2026.

  • MPM BioImpact reported no remaining Rocket Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • MPM BioImpact sold 1,586,076 Rocket Pharmaceuticals shares in Q1 2026, an estimated $5.57M.
  • MPM BioImpact first reported a position in Rocket Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • MPM BioImpact's Rocket Pharmaceuticals position peaked at $19.7M in Q3 2024.
  • 199 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.